GPATCH2 Inhibitors
GPATCH2 Inhibitors encompass a variety of compounds that diminish the functional activity of GPATCH2 through their targeted action on various signaling pathways and cellular processes integral to RNA splicing, in which GPATCH2 plays a regulatory role. Staurosporine, as a non-selective protein kinase inhibitor, reduces GPATCH2 activity by interfering with the phosphorylation required for its function. Similarly, LY 294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, andrapamycin, an mTOR pathway inhibitor, both lead to a decrease in GPATCH2 function by disrupting processes upstream of RNA splicing, such as protein synthesis and processing. Leptomycin B compounds this effect by inhibiting nuclear export and trapping splicing factors in the nucleus, further diminishing GPATCH2's role in splicing. Direct inhibitors of splicing, such as pladienolide B, meayamycin B, sudemycin E, isoginkgetin, spliceostatin A, madrasin, and E7107, target the spliceosome and its associated factors, thereby decreasing the efficiency of the splicing process where GPATCH2 is involved. These compounds exert their inhibitory effect by binding to components of the spliceosome, preventing its proper assembly or function, which in turn reduces GPATCH2's participation in the regulation of splicing.
Additionally, silvestrol, by inhibiting eukaryotic initiation factor 4A (eIF4A), indirectly lowers GPATCH2 activity by reducing the translation of proteins required for splicing. Collectively, these inhibitors function through a convergence of pathways that are fundamental to the maintenance of RNA splicing integrity. The cumulative effect of these inhibitors is a comprehensive decrease in GPATCH2's activity within the cell, achieved through the targeted disruption of various stages of gene expression and post-transcriptional modification. This multi-faceted approach ensures that GPATCH2's functional capabilities are effectively diminished, highlighting the interconnected nature of cellular processes and the dependency of GPATCH2's activity on the proper functioning of these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. GPATCH2 function relies on phosphorylation states that can be altered by kinase activity. Inhibition of these kinases by staurosporine can, therefore, diminish the functional activity of GPATCH2 by preventing its necessary phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Given that PI3K signaling is integral to numerous cellular processes including mRNA processing, LY294002's suppression of PI3K can lead to an indirect decrease in GPATCH2 function, which is involved in RNA splicing. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is critical for cap-dependent translation, affecting the synthesis of various proteins. Inhibiting mTOR with rapamycin may result in the reduced functional activity of GPATCH2 by lowering the translation of proteins involved in splicing mechanisms where GPATCH2 is crucial. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Leptomycin B is an inhibitor of nuclear export. By preventing protein export from the nucleus, it affects splicing factor dynamics. This action can diminish GPATCH2's function as it is involved in the nuclear RNA splicing process. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B is a splicing inhibitor that targets the spliceosome, a complex essential for proper RNA splicing. As GPATCH2 is involved in RNA splicing, the inhibition of spliceosomal activity by pladienolide B can lead to a decrease in GPATCH2’s functional role in splicing. | ||||||
Isoginkgetin | 548-19-6 | sc-507430 | 5 mg | $225.00 | ||
Isoginkgetin is a pre-mRNA splicing inhibitor. By inhibiting the splicing process, isoginkgetin can indirectly diminish the activity of GPATCH2, which participates in the regulation of RNA splicing. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A inhibits the spliceosome by binding to the SF3b complex. Since GPATCH2 is a regulator of RNA splicing, the inhibition of the spliceosome by spliceostatin A would lead to a decrease in GPATCH2’s role in splicing. | ||||||
Madrasin | 374913-63-0 | sc-507563 | 100 mg | $750.00 | ||
Madrasin is a small molecule that disrupts spliceosome assembly. By interfering with the proper formation of the spliceosome, madrasin can indirectly diminish the activity of GPATCH2 in splicing. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Silvestrol is an inhibitor of eukaryotic initiation factor 4A (eIF4A), which is necessary for mRNA translation. By inhibiting eIF4A, silvestrol can indirectly lower the activity of GPATCH2 by reducing the pool of proteins necessary for the splicing process. | ||||||